BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38000020)

  • 21. Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer.
    Guarducci C; Nardone A; Russo D; Nagy Z; Heraud C; Grinshpun A; Zhang Q; Freelander A; Leventhal MJ; Feit A; Cohen Feit G; Feiglin A; Liu W; Hermida-Prado F; Kesten N; Ma W; De Angelis C; Morlando A; O'Donnell M; Naumenko S; Huang S; Nguyen QD; Huang Y; Malorni L; Bergholz JS; Zhao JJ; Fraenkel E; Lim E; Schiff R; Shapiro GI; Jeselsohn R
    Clin Cancer Res; 2024 May; 30(9):1889-1905. PubMed ID: 38381406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma.
    Valencia-Sama I; Kee L; Christopher G; Ohh M; Layeghifard M; Shlien A; Hayes MN; Irwin MS
    Cancer Res Commun; 2023 Dec; 3(12):2608-2622. PubMed ID: 38032104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of H3K27me3 immunohistochemistry and combination of NF1 and p16 deletions by fluorescence in situ hybridization in the differential diagnosis of malignant peripheral nerve sheath tumor and its histological mimics.
    Sugita S; Aoyama T; Emori M; Kido T; Takenami T; Sakuraba K; Terai K; Sugawara T; Tsujiwaki M; Hasegawa T
    Diagn Pathol; 2021 Aug; 16(1):79. PubMed ID: 34461930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma.
    Willobee BA; Gaidarski AA; Dosch AR; Castellanos JA; Dai X; Mehra S; Messaggio F; Srinivasan S; VanSaun MN; Nagathihalli NS; Merchant NB
    Mol Cancer Ther; 2021 Jul; 20(7):1246-1256. PubMed ID: 34001634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of Erb-B2 Receptor Tyrosine Kinase 3 and Associated Regulatory Pathways Potently Impairs Malignant Peripheral Nerve Sheath Tumor Proliferation and Survival.
    Black LE; Longo JF; Anderson JC; Carroll SL
    Am J Pathol; 2023 Sep; 193(9):1298-1318. PubMed ID: 37328102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo.
    Zhang YX; Sicinska E; Czaplinski JT; Remillard SP; Moss S; Wang Y; Brain C; Loo A; Snyder EL; Demetri GD; Kim S; Kung AL; Wagner AJ
    Mol Cancer Ther; 2014 Sep; 13(9):2184-93. PubMed ID: 25028469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer.
    Wu C; Peng S; Pilié PG; Geng C; Park S; Manyam GC; Lu Y; Yang G; Tang Z; Kondraganti S; Wang D; Hudgens CW; Ledesma DA; Marques-Piubelli ML; Torres-Cabala CA; Curry JL; Troncoso P; Corn PG; Broom BM; Thompson TC
    Mol Cancer Ther; 2021 Sep; 20(9):1680-1691. PubMed ID: 34158347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
    Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
    Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Galectin-1 inhibition induces cell apoptosis through dual suppression of CXCR4 and Ras pathways in human malignant peripheral nerve sheath tumors.
    Shih TC; Fan Y; Kiss S; Li X; Deng XN; Liu R; Chen XJ; Carney R; Chen A; Ghosh PM; Lam KS
    Neuro Oncol; 2019 Nov; 21(11):1389-1400. PubMed ID: 31127849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Knockdown of HMGA2 regulates the level of autophagy via interactions between MSI2 and Beclin1 to inhibit NF1-associated malignant peripheral nerve sheath tumour growth.
    Yang K; Guo W; Ren T; Huang Y; Han Y; Zhang H; Zhang J
    J Exp Clin Cancer Res; 2019 May; 38(1):185. PubMed ID: 31053152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient-derived orthotopic xenografts, cell lines and tumor entities.
    Creus-Bachiller E; Fernández-Rodríguez J; Magallón-Lorenz M; Ortega-Bertran S; Navas-Rutete S; Romagosa C; Silva TM; Pané M; Estival A; Perez Sidelnikova D; Morell M; Mazuelas H; Carrió M; Lausová T; Reuss D; Gel B; Villanueva A; Serra E; Lázaro C
    Mol Oncol; 2024 Apr; 18(4):895-917. PubMed ID: 37798904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic Status of
    Peacock JD; Pridgeon MG; Tovar EA; Essenburg CJ; Bowman M; Madaj Z; Koeman J; Boguslawski EA; Grit J; Dodd RD; Khachaturov V; Cardona DM; Chen M; Kirsch DG; Maina F; Dono R; Winn ME; Graveel CR; Steensma MR
    Cancer Res; 2018 Jul; 78(13):3672-3687. PubMed ID: 29720369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chromosomal translocations inactivating CDKN2A support a single path for malignant peripheral nerve sheath tumor initiation.
    Magallón-Lorenz M; Fernández-Rodríguez J; Terribas E; Creus-Batchiller E; Romagosa C; Estival A; Perez Sidelnikova D; Salvador H; Villanueva A; Blanco I; Carrió M; Lázaro C; Serra E; Gel B
    Hum Genet; 2021 Aug; 140(8):1241-1252. PubMed ID: 34059954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined SHPments: An Effective Therapeutic Strategy for MPNST.
    Aplin AE; Capparelli C
    Cancer Res; 2021 Jan; 81(2):266-267. PubMed ID: 33452215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer.
    de Leeuw R; McNair C; Schiewer MJ; Neupane NP; Brand LJ; Augello MA; Li Z; Cheng LC; Yoshida A; Courtney SM; Hazard ES; Hardiman G; Hussain MH; Diehl JA; Drake JM; Kelly WK; Knudsen KE
    Clin Cancer Res; 2018 Sep; 24(17):4201-4214. PubMed ID: 29739788
    [No Abstract]   [Full Text] [Related]  

  • 36. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
    Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
    Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.
    Williams KB; Largaespada DA
    Genes (Basel); 2020 Apr; 11(5):. PubMed ID: 32353955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors.
    Mo W; Chen J; Patel A; Zhang L; Chau V; Li Y; Cho W; Lim K; Xu J; Lazar AJ; Creighton CJ; Bolshakov S; McKay RM; Lev D; Le LQ; Parada LF
    Cell; 2013 Feb; 152(5):1077-90. PubMed ID: 23434321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma.
    Li X; Seebacher NA; Garbutt C; Ma H; Gao P; Xiao T; Hornicek FJ; Duan Z
    Cell Death Dis; 2018 May; 9(5):446. PubMed ID: 29670090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: A nationwide cohort study.
    Martin E; Coert JH; Flucke UE; Slooff WM; van de Sande MAJ; van Noesel MM; Grünhagen DJ; Wijnen MHWA; Verhoef C
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28138. PubMed ID: 31889416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.